无环鸟苷联合干扰素，双氯芬酸钠治疗单纯疱疹病毒性角膜炎

目的：观察无环鸟苷联合干扰素,双氯芬酸钠治疗单纯疱疹病毒性角膜炎的效果。方法：对160例（186眼）患者随机分为治疗组80例（97眼）和对照组80例（89例）治疗组患者滴0．1％无环鸟苷滴眼液,重组干扰素α1b滴眼液（10μg/ml）、0．1％双氯芬酸钠滴眼液,对照组滴用0．1％无环鸟苷滴眼液,结果：治疗组治愈率（91．75％）,对照治愈率（75．28％）经统计学处理,差异有显著意义（P＜0．01）;治疗组有效率（96．90％,对照组有效率（88．75％）,差异有显著意义（P＜0．05）,结论：无环鸟苷联合干扰素,双氯芬酸钠治疗单纯疱疹病毒性角膜炎疗效肯定,治愈率高,是合理安全的用药方法。     

Fn滴眼液治疗单疱病毒性深层角膜炎的临床观察

目的探讨纤维结合蛋白(Nfibronectin Fn)在单疱病毒性深层角膜炎治疗中的作用。方法观察治疗组27例27眼(初发8例8眼，复发19例19眼)单疱病毒性深层角膜炎患者滴用潍坊市中心血站制备的Fn滴眼液(富含纤维结合蛋白的冷沉淀滴眼液)的临床疗效。并与对照组(不用Fn滴眼液)26例28眼比较其治愈率、有效率、疗程及复发率。结果治疗组治愈25眼，好转2眼；治愈率92．6％，有效率100％；治疗天数平均21天；随访2年，复发1眼，复发率为3．7％。对照组治愈23眼，好转5眼；治愈率为82．1％，有效率100％。治疗天数平均30．5天；随访2年，复发5例5眼，复发率17．9％。两者比较，有效率及治愈率差异无显著性，但治疗组比对照组病程明显缩短，平均缩短9．5天。不用Fn治疗的，其复发率明显提高。结论Fn滴眼液可增强角膜弹性，促进角膜再生，加速角膜缺损的修复，可提高疗效，缩短疗程，降低复发率，对减轻角膜云翳的形成和视力的提高具有重要的意义，且安全、方便、无不良反应。     

球结膜下注射转移因子在治疗单纯疱疹病毒性角膜炎的临床应用

目的观察球结膜下注射转移因子对治疗单纯疱疹病毒性角膜炎（ HSK）的疗效。方法86例（92只眼）HSK患者随机分成两组。 A组（45例49只眼）予球结膜下注射转移因子,B组（41例43只眼）予球结膜下注射α-干扰素及α-干扰素滴眼,两组均常规滴用阿昔洛韦滴眼液。结果 A组疗效优于B组（ P ＜0．05）。结论球结膜下注射转移因子可以提高患眼局部免疫力,配合抗病毒治疗HSK效果好,操作简单,无明显副作用。     

典必殊联合阿昔洛韦治疗单疱病毒性角膜炎的疗效观察

目的:探讨典必殊滴眼液联合阿昔洛韦(无环鸟苷,ACV)滴眼液治疗单疱病毒性角膜炎(herpes simplex keratitis,HSK)的疗效。方法:将43例46眼HSK患者随机分两组,典必殊治疗组23例25眼,贝复舒对照组20例21眼,将其临床资料进行回顾性分析,观察临床治疗效果。结果:浅层型全部治愈,深层型典必殊治疗组有效率87.5%,贝复舒对照组有效率60.0%,治愈时间典必殊治疗组平均12d,贝复舒治疗组平均17d;复发率典必殊治疗组34.8%,贝复舒对照组55.0%。两组相比差异有统计学意义(P<0.05)。结论:典必殊联合阿昔洛韦治疗HSK,具有明显的协同作用,能提高治愈率,缩短病程,降低复发,尤其对深层型单疱病毒性角膜炎疗效显著。     

rIL-2治疗单纯疱疹性角膜炎的临床研究

目的：研究重组白细胞介素Ⅱ（rIL-2）治疗单纯疱疹性角膜炎（HSK）的疗效及预防复发的作用。方法：将确诊的HSK患者随机分为2组,治疗组38例在应用无环鸟苷滴眼液同时联合rIL-2局部及全身应用;对照组30例单纯应用无环鸟苷治疗。治愈后均随访2年。结果：联合用药治疗组的病程较对照组明显缩短（P＜0．01）。随访结果显示,治疗组的复发率较对照组明显降低（P＜0．05）。结论：临床应用rIL-2联合抗病毒药物治疗HSK疗效明显,可缩短病程、降低复发率。临床观察无明显不良反应。     

HSK合并白内障行超声乳化术后的疗效及临床用药观察

目的:观察单纯疱疹病毒性角膜炎(Herpes simplex keratitis,HSK)合并白内障患者行白内障超声乳化术后视力变化及术后应用抗病毒药物预防单纯疱疹病毒性角膜炎复发的疗效。方法:单纯疱疹病毒性角膜炎合并白内障22例22眼行白内障超声乳化+人工晶状体植入术,术后随机分为两组,治疗组给予口服阿昔洛韦及滴用更昔洛韦凝胶;对照组仅给予滴用更昔洛韦凝胶。观察术后视力变化情况;分析单纯疱疹病毒性角膜炎复发的情况。结果:术后6mo随访,治疗组和对照组视力均获得提高;治疗组无1例出现单纯疱疹病毒性角膜炎的复发;对照组也仅有1例于术后6mo复发,差异无显著性。结论:在抗病毒药物的保护下,>6mo未复发的单纯疱疹病毒性角膜炎不是白内障的手术禁忌,白内障手术能有效改善HSK合并白内障患者的视力;仅滴用更昔洛韦凝胶亦能有效预防白内障术后单纯疱疹病毒性角膜炎的复发。     

麻疹减毒活疫苗治疗单纯疱疹病毒性角膜炎临床疗效随访观察

报告以麻疹减毒活疫苗治疗单纯疱疹病毒性角膜炎30例，设对照组30例。近期疗效观察（5～8周）麻苗组治愈27例（90％）。对照组治愈12例（40％）。随访8～12年，麻苗组24例有4例复发（16％）；对照组22例有16例复发（73％）。提示麻疹减毒活疫苗连续注射后，可较长时期诱生干扰素或其它非特异性免疫反应，使麻苗组复发率明显低于对照组。     

鱼腥草联合贝复舒(bFGF)治疗复发性单纯疱疹性角膜炎30例报告

目的　观察鱼腥草联合贝复舒 (b FGF滴眼液 )对复发性单纯疱疹性角膜炎的疗效。方法　治疗组 30例用鱼腥草注射液静脉滴注、点眼及贝复舒点眼 ,对照组 2 9例用无环鸟苷注射液静脉滴注联合局部点眼 ,随访 1～2年 ,平均为 15月。结果　治疗组痊愈率为 86 .6 2 % ,有效率为 93.33% ,与对照组痊愈率 5 1.72 %和有效率6 9.0 7%比较 ,差异有显著意义 (P <0 .0 5 ) ;平均治愈天数治疗组 (18.2 1± 2 .4 5天 )少于对照组 (2 0 .36± 2 .2 3天 )(P <0 .0 1) ;随访病例治疗组 2 6例 ,复发 1例 ,复发率为 3.85 % ,对照组 15例 ,复发 5例 ,复发率为 33.33% ,两组比较 ,差异有显著意义 (P <0 .0 5 )。结论　鱼腥草联合贝复舒可提高复发性单纯疱疹性角膜炎的治愈率 ,缩短疗程 ,并有利于角膜组织最佳修复 ,不留或少留瘢痕 ,对预防和减少复发及其它并发症也有积极作用     

继发性单纯疱疹病毒性角膜炎治疗分析

目的 探讨单纯疱疹病毒性角膜炎(HSK)的治疗效果。方法 对87例(94只眼)HSK患者根据不同的临床类型分别给予用药，其中对34只眼深层非溃疡型HSK患者，联合应用激素治疗，并观察临床治疗效果。结果 浅层型53只眼全部治愈，治愈率为100％；深层型治愈率为85．37％(35／41)。结论 对HSK患者应根据不同的临床类型选择合理用药，可有效地提高治愈率，并降低复发率。     

膦甲酸钠滴眼液治疗上皮型单纯疱疹病毒性角膜炎

目的：探讨膦甲酸钠滴眼液治疗上皮型单纯疱疹病毒性角膜炎（herpes simplex keratitis,HSK）的近中期疗效。 方法：选取2008-03/2009-12在钟祥市人民医院眼科门诊确诊的60例60眼上皮型HSK患者,将其随机分为对照组和试验组两组。对照组采用更昔洛韦滴眼液,8次/d;试验组采用膦甲酸钠滴眼液,6次/d,用药时间均为14d。观察治疗后3,7,10,14d的角膜溃疡面积、眼部症状体征评分,统计治愈率。随访2a,统计随访期间上皮型HSK的复发率。 结果:两组患者治疗前的一般情况、症状体征评分无显著差异（P>0.05）。与治疗前相比,治疗后两组患者的角膜溃疡面积、眼部症状体征评分均明显下降（P<0.05）,但两组之间的角膜溃疡面积、眼部症状体征评分和治愈率均无明显差异（P>0.05）。随访2a期间,试验组和对照组患者的复发率分别是13%,27%,差异有显著性（P<0.05）。 结论:膦甲酸钠滴眼液在治疗上皮型HSK的近期疗效与更昔洛韦滴眼液相同,但中期复发率低于更昔洛韦滴眼液。     

Strabisme Alternant - Etude clinique - traitement

The author defines motor and sensory alternation: the term alternation should not be used in isolation, it should always be accompanied by the name of the parameter concerned. Sensory alternation is always found together with motor alternation but the reverse is not true.The examining criteria for a diagnosis of sensory alternation are given, sensory alternation must not be confused with alternating inhibition. Working from clinical observations of cases of motor alternating strabismus, the author selects 2 types of binocular sensory relations which allow one to differentiate between:- cases of primary alternating strabismus- cases of secondary alternating strabismusThese forms will develop in different ways; in both cases a cure is possible providing that the right treatment is prescribed and once prescribed carefully followed, etc. It is always a case of serious forms of strabismus whose developmental period is spread over several years.According to the authors, the frequency of cases of true primary strabismus is from 1–3%, the frequency of cases of secondary alternating strabismus varies according to the type of therapy practised on cases of monocular strabismus with amblyopia. These latter will become cases of alternating strabismus under the influence of certain types of therapy carried out over several years (penalization, rocking, alternated occlusion, etc...).Experimental data on kittens confirm clinical data; kittens placed in abnormal environments during the sensitive period will show modification in the distribution of cortical cells and the absence of binocular cells (either because the excitation of the two eyes was not simultaneous, or not identical: artificial strabismus, occlusion, opaque glasses). This disturbances become irreversible after a certain period of exposure (a function of age, length of exposure, etc...).It is thus necessary to bear in mind: 1) the iatrogenic risks of certain orthoptic treatments, 2) the necessity for a binocular form of treatment as soon as possible, as once a certain stage is passed, cortical plasticity diminishes and the elaboration of normal binocular relations becomes impossible.

---

     

Effects of Adenosine Agonists on Intraocular Pressure and Aqueous Humor Dynamics in Cynomolgus Monkeys

The effects of single or multiple topical doses of the relatively selective A₁adenosine receptor agonists (R)-phenylisopropyladenosine (R-PIA) and N⁶-cyclohexyladenosine (CHA) on intraocular pressure (IOP), aqueous humor flow (AHF) and outflow facility were investigated in ocular normotensive cynomolgus monkeys. IOP and AHF were determined, under ketamine anesthesia, by Goldmann applanation tonometry and fluorophotometry, respectively. Total outflow facility was determined by anterior chamber perfusion under pentobarbital anesthesia. A single unilateral topical application of R-PIA (20–250 μg) or CHA (20–500 μg) produced ocular hypertension (maximum rise=4.9 or 3.5 mmHg) within 30 min, followed by ocular hypotension (maximum fall=2.1 or 3.6 mmHg) from 2–6 hr. The relatively selective adenosine A₂antagonist 3,7-dimethyl-1-propargylxanthine (DMPX, 320 μg) inhibited the early hypertension, without influencing the hypotension. Neither 100 μg R-PIA nor 500 μg CHA clearly altered AHF. Total outflow facility was increased by 71% 3 hr after 100 μg R-PIA. In conclusion, the early ocular hypertension produced by topical adenosine agonists in cynomolgus monkeys is associated with the activation of adenosine A₂receptors, while the subsequent hypotension appears to be mediated by adenosine A₁receptors and results primarily from increased outflow facility.